Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC

Sponsor
Sun Yat-sen University
Study ID
NCT04682249
Phase
PHASE2
Status
Withdrawn

Conditions

  • ICC

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Systemic Chemotherapy — DRUG
    Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
  • Sintilimab — DRUG
    Sintilimab
  • Apatinib — DRUG
    Apatinib

Study Details

This study were designed to verify the better method of survival for metastatic ICC. Since the traditional method for metastatic ICC was GEMOX(first-line treatment from NCCN guideline), our previous study found similar results from FOLFOX (second-line treatment from NCCN guideline) compared with GEMOX. Our current study were conducted for further investigation to verify the better method for metastatic ICC.

Key Dates

Start date
Dec 1, 2020
Status verified
Feb 2021
Primary completion
Feb 1, 2021
Completion
Feb 1, 2021

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Systemic Chemotheray, Apatinib plus Sintilimab

Primary Outcome Measure

Objective response rate [ Time Frame: 6 months ]